You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Claims for Patent: 8,791,140

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,791,140

Title:	Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Abstract:	The present invention relates to crystalline polymorphic and amorphous form of 6-[2-(methylcarbamoyl)phenyl sulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one polymorphic form and to the therapeutic or prophylactic use of such polymorphic forms and compositions.
Inventor(s):	Campeta; Anthony Michael (Ledyard, CT), Chekal; Brian Patrick (Niantic, CT), Singer; Robert Alan (Niantic, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	12/594,575
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,791,140
Patent Claims:	1. A crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazo- le, wherein said crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2.theta.) of 6.0.+-.0.1 and further comprising at least one peak at diffraction angle (2.theta.) selected from 11.5.+-.0.1, 21.0.+-.0.1 and 26.9.+-.0.1. 2. A crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazo- le, wherein said crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2.theta.) of 6.0.+-.0.1, 11.9.+-.0.1 and 22.8.+-.0.1. 3. A crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazo- le, wherein said crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2.theta.) of 11.9.+-.0.1 and 21.0.+-.0.1, and further comprising at least one peak at diffraction angle (2.theta.) selected from 22.8.+-.0.1, 23.1.+-.0.1 and 26.9.+-.0.1. 4. A crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazo- le, wherein said crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2.theta.) of 11.5.+-.0.1 and 15.6.+-.0.1, and further comprising at least one peak at diffraction angle (2.theta.) selected from 16.2.+-.0.1 and 16.5.+-.0.1. 5. A crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazo- le, wherein said crystalline form has a solid state NMR spectrum comprising .sup.13C chemical shifts at 150.1.+-.0.2, 136.6.+-.0.2, 135.+-.0.2, 116.9.+-.0.2 and 27.5.+-.0.2 ppm. 6. A crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazo- le, wherein said crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2.theta.) of 6.0.+-.0.1 and 11.5.+-.0.1 and wherein said crystalline form has a solid state NMR spectrum comprising .sup.13C chemical shifts at 150.1.+-.0.2 and 27.5.+-.0.2 ppm.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.